Second round Lutathera for intestinal NET after regrowth
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study looks at whether giving Lutathera again (a second round) can control an intestinal neuroendocrine tumor (NET) that came back or progressed after the first treatment. It mainly targets adults whose scan shows tumors still take up the right “target” signal and who previously benefited for at least 12 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your intestinal NET must be grade 1 or grade 2 (G1 or G2) confirmed by tumor tissue testing.
- You previously had 4 cycles of Lutathera, and the disease was controlled for at least 12 months after that first round, then later progressed.
- You must have approval to start a second round of Lutathera, based on a specialist NET team review (RENATEN) and within the French insurance process.
- Your latest scan must show tumor uptake on a “somatostatin receptor” scan (SSTR-positive), with most lesions lighting up.
- Blood tests and general health must be good enough for treatment (for example, adequate bone marrow function and limited organ problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This Phase 1 study tests how well Lutathera combined with ASTX727 can treat neuroendocrine tumors. It looks mainly at whether the combination can be given safely and effectively for people whose tumors have grown or not tolerated standard first treatment.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
This study looks at whether a simple blood test (inflammation score) can predict how well the drug Lu-177 oxodotreotide (Lutathera) will work for people with midgut neuroendocrine tumors that have grown or spread. It may help doctors understand who benefits most from this treatment.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.